BOTOX in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 25 Oct 2018 Status changed from active, no longer recruiting to completed.
- 22 Aug 2018 This trial has been completed in Czech Republic.
- 26 May 2018 This trial has been completed in Germany as per Eudra.